Chartwell Investment Partners LLC Trims Stake in Eli Lilly And Co (NYSE:LLY)

Chartwell Investment Partners LLC reduced its position in shares of Eli Lilly And Co (NYSE:LLY) by 51.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,645 shares of the company’s stock after selling 20,715 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Eli Lilly And Co were worth $3,225,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cpwm LLC increased its holdings in shares of Eli Lilly And Co by 0.7% in the 1st quarter. Cpwm LLC now owns 9,349 shares of the company’s stock valued at $1,297,000 after acquiring an additional 65 shares during the period. Old North State Trust LLC grew its stake in Eli Lilly And Co by 1.2% during the 2nd quarter. Old North State Trust LLC now owns 5,660 shares of the company’s stock worth $929,000 after buying an additional 66 shares during the last quarter. Endurance Wealth Management Inc. grew its stake in Eli Lilly And Co by 1.6% during the 2nd quarter. Endurance Wealth Management Inc. now owns 4,141 shares of the company’s stock worth $680,000 after buying an additional 66 shares during the last quarter. Parcion Private Wealth LLC grew its stake in Eli Lilly And Co by 3.5% during the 2nd quarter. Parcion Private Wealth LLC now owns 1,929 shares of the company’s stock worth $322,000 after buying an additional 66 shares during the last quarter. Finally, Clifford Swan Investment Counsel LLC grew its stake in Eli Lilly And Co by 1.3% during the 1st quarter. Clifford Swan Investment Counsel LLC now owns 5,289 shares of the company’s stock worth $734,000 after buying an additional 70 shares during the last quarter. Institutional investors own 77.32% of the company’s stock.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 212,337 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $162.92, for a total value of $34,593,944.04. Following the transaction, the insider now owns 112,194,732 shares in the company, valued at approximately $18,278,765,737.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 11,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $170.00, for a total value of $1,870,000.00. Following the completion of the transaction, the senior vice president now owns 18,646 shares in the company, valued at approximately $3,169,820. The disclosure for this sale can be found here. Insiders sold a total of 555,236 shares of company stock worth $91,393,391 in the last 90 days. 0.09% of the stock is currently owned by insiders.

Eli Lilly And Co stock opened at $150.29 on Friday. The company’s fifty day moving average price is $160.88 and its 200 day moving average price is $148.62. Eli Lilly And Co has a 1 year low of $101.36 and a 1 year high of $170.75. The stock has a market capitalization of $143.74 billion, a P/E ratio of 24.40, a P/E/G ratio of 1.32 and a beta of 0.26. The company has a debt-to-equity ratio of 4.37, a quick ratio of 0.86 and a current ratio of 1.11.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Thursday, July 30th. The company reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.31. The firm had revenue of $5.50 billion for the quarter, compared to analysts’ expectations of $5.77 billion. Eli Lilly And Co had a net margin of 24.48% and a return on equity of 200.78%. The firm’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.50 EPS. Sell-side analysts predict that Eli Lilly And Co will post 7.3 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $0.74 dividend. The ex-dividend date is Thursday, August 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.97%. Eli Lilly And Co’s payout ratio is currently 49.01%.

Several research analysts recently weighed in on LLY shares. Cantor Fitzgerald boosted their target price on Eli Lilly And Co from $156.00 to $185.00 and gave the stock an “overweight” rating in a research note on Friday, April 24th. UBS Group cut Eli Lilly And Co from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $157.00 to $158.00 in a research report on Monday, April 20th. Bank of America reaffirmed a “buy” rating and set a $180.00 price target on shares of Eli Lilly And Co in a research report on Friday, June 19th. Zacks Investment Research lowered their price target on Eli Lilly And Co to $156.00 in a research report on Wednesday, April 29th. Finally, Guggenheim raised Eli Lilly And Co from a “neutral” rating to a “buy” rating and set a $182.00 price target for the company in a research report on Tuesday, June 16th. One analyst has rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $168.58.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Yield Curve

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.